ArticleMaterials today. Bio2026
BMSC-targeting aptamer conjugation enhances bone delivery of a rice bran peptide to mitigate osteoporosis via eIF3L.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is frequently accompanied by a shift in the fate of bone marrow mesenchymal stromal cells (BMSCs) from osteogenesis toward adipogenesis, contributing to bone-fat imbalance and fragility fractures. Here, we evaluated a naturally occurring eight-amino acid rice bran-derived peptide, RBAP (KHNRGDEF), together with an aptamer-RBAP conjugate designed to improve bone accumulation via a previously identified BMSC-targeting nucleic acid aptamer. In ovariectomized mice, RBAP administered either preventively (early after ovariectomy) or therapeutically (after osteoporotic phenotypes had developed) preserved trabecular microarchitecture, improved mechanical properties, reduced marrow adiposity, and accelerated osteoporotic fracture healing. RBAP also conferred bone-protective effects in models of natural aging and disuse osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.